Ixico PLC on Monday said it has signed a supply agreement with Life Molecular Imaging GmbH, in a deal the company says will complement its ‘well-established PET imaging services and image data analytics’.

The neuroscience focused advanced analytics company said the agreement is for the supply of LMI’s Neuraceq Amyloid PET tracer for use in pharma-sponsored clinical trials.

Ixico explained that Neuraceq is a diagnostic agent that improves early detection and characterization of chronic and life-threatening diseases such as Alzheimer’s.

It noted that it will extend its service offering to providing Neuraceq PET tracer supply to complement Ixico’s ‘well-established PET imaging services and image data analytics.’

LMI’s provision of tracer supply to imaging centres together with IXICO’s oversight of imaging will minimise the operational burden to trial sponsors and will improve patient experience, ultimately driving study eligibility and efficacy endpoint delivery.

Chief Executive Officer Giulio Cerroni commented: ’’Ixico is committed to the continuous development of our suite of AI enabled analytics and reader services for innovative new PET tracers and so we are delighted to be partnering with LMI to improve access and supply to LMI’s Neuraceq. We anticipate that the extension of this Neuraceq tracer co-ordination service from Ixico will be very well received by our global biopharmaceutical sponsors.‘

Shares in Ixico were down 2.5% to 8.54 pence each in London on Monday afternoon.

Copyright 2024 Alliance News Ltd. All Rights Reserved.